JPMorgan Chase Bank, National Association London Branch Canary Wharf London E14 5JP England November 29, 2013Letter Agreement • December 4th, 2013 • Albany Molecular Research Inc • Services-commercial physical & biological research • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Albany Molecular Research, Inc. (“Company”) to JPMorgan Chase Bank, National Association, London Branch (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
To: Albany Molecular Research, Inc. 26 Corporate Circle Albany, New York 12212 Attention: Michael M. Nolan, Vice President Finance, Chief Financial Officer and Treasurer Telephone No.: (518) 512-2000 Re: Amendment to Call Option TransactionLetter Agreement • December 4th, 2013 • Albany Molecular Research Inc • Services-commercial physical & biological research • New York
This letter agreement (this “Amendment”) amends the terms and conditions of the transaction (the “Transaction”) evidenced by the letter agreement re: Call Option Transaction between JPMorgan Chase Bank, National Association, London Branch (“Dealer”) and Albany Molecular Research, Inc. (“Counterparty”) dated as of November 19, 2013 (the “Confirmation”).
To: Albany Molecular Research, Inc. 26 Corporate Circle Albany, New York 12212 Attention: Michael M. Nolan, Vice President Finance, Chief Financial Officer and Treasurer Telephone No.: (518) 512-2000 Re: Amendment to Call Option TransactionLetter Agreement • December 4th, 2013 • Albany Molecular Research Inc • Services-commercial physical & biological research • New York
This letter agreement (this “Amendment”) amends the terms and conditions of the transaction (the “Transaction”) evidenced by the letter agreement re: Call Option Transaction between Morgan Stanley & Co. International plc (“Dealer”) and Albany Molecular Research, Inc. (“Counterparty”) dated as of November 19, 2013 (the “Confirmation”).
